News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

QTL Biosystems, LLC Enables Alzheimer's Researchers With The Release Of A Gamma Secretase HTS Assay

10/19/2005 5:09:42 PM

SANTA FE, N.M., Jan. 15 /PRNewswire/ -- QTL Biosystems, LLC, a provider of innovative solutions for bio-detection, drug discovery, and life science research, announced today the release of the QTL LIGHTSPEED(TM) gamma- secretase Assay Kit. This assay utilizes a fluorescent polyelectrolyte-based super-quenching polymer that offers several advantages over conventional small molecule fluorescence. The QTL LIGHTSPEED(TM) platform provides single step, instantaneous, homogenous assays, and addresses a broad spectrum of drug targets in high-throughput screening.

The QTL LIGHTSPEED(TM) technology requires no radioactive material, antibodies, or wash steps. The platform is a simple mix and read format. "With the commercialization of LIGHTSPEED(TM), our assay teams are able to create a new assay in 4-6 weeks time. The ability to deliver in this time frame is going to further support pharma and biotech in their quest for specific targets," stated Duncan McBranch, Ph.D., Co-founder and COO at QTL Biosystems.

A key event in the pathogenesis of Alzheimer's disease (AD) is the deposition of senile plaques consisting largely of a peptide known as beta- amyloid (Abeta) that is derived from the amyloid precursor protein (APP). A proteolytic activity called gamma-secretase cleaves APP in the transmembrane domain and is required for Abeta generation. Aberrant gamma-secretase cleavage of APP underlies the majority of early onset, familial Alzheimer's Disease.

"The release of QTL LIGHTSPEED(TM) gamma-secretase along with beta secretase, is extremely important in that it provides an assay suite that will allow researchers to identify components and pathways by which the gamma- secretase activity is regulated. This is crucial to understanding the mechanisms underlying Alzheimer's Disease pathogenesis, and may provide new diagnostic tools and therapeutic targets," stated David Whitten, Ph.D., Co-founder and CTO at QTL Biosystems.

About QTL Biosystems

QTL Biosystems, LLC is a supplier of amplification technologies for bioassays that accelerate and improve drug discovery, bio-detection, and other life sciences research. The Company's assay solutions facilitate the high throughput and cost effective identification and evaluation of drug candidates. The Company's advanced core technologies integrate its expertise in chemistry, molecular and cell biology and instrumentation. QTL Biosystems enables its customers to improve research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs.

Contact: Paul Gindlesperger Director of Sales and Marketing QTL Biosystems, LLC 2778 Agua Fria Street, Bldg. C Santa Fe, NM 87507 (505) 424-1000, ext. 116 bd@qtlbio.com

This release was issued through eReleases(TM). For more information, visit

QTL Biosystems, LLC

CONTACT: Paul Gindlesperger, Director of Sales and Marketing,QTL Biosystems, LLC, +1-505-424-1000, ext. 116,

Read at

comments powered by Disqus